Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

66 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Integrated safety in tocilizumab clinical trials.
Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Schiff MH, et al. Among authors: vernon e. Arthritis Res Ther. 2011;13(5):R141. doi: 10.1186/ar3455. Epub 2011 Sep 1. Arthritis Res Ther. 2011. PMID: 21884601 Free PMC article. Clinical Trial.
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Kremer JM, et al. Among authors: vernon e. Arthritis Rheum. 2011 Mar;63(3):609-21. doi: 10.1002/art.30158. Arthritis Rheum. 2011. PMID: 21360490 Free article. Clinical Trial.
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
Cooles FAH, Tarn J, Lendrem DW, Naamane N, Lin CM, Millar B, Maney NJ, Anderson AE, Thalayasingam N, Diboll J, Bondet V, Duffy D, Barnes MR, Smith GR, Ng S, Watson D, Henkin R, Cope AP, Reynard LN, Pratt AG; RA-MAP Consortium, Isaacs JD. Cooles FAH, et al. Ann Rheum Dis. 2022 Jun 9;81(9):1214-23. doi: 10.1136/annrheumdis-2022-222370. Online ahead of print. Ann Rheum Dis. 2022. PMID: 35680389 Free PMC article.
66 results